Fresenius Medical Care Cuts Top of 2026 Outlook
The German dialysis provider lowered the upper end of its operating income forecast after weak US treatment volumes in the third quarter.
Updated on Nov. 3, 2026 in Healthcare
Live Poll
Do you think healthcare is getting better or worse for people like you?
Fresenius Medical Care reported third-quarter operating income excluding special items of €545 million ($610 million), down 5% from €574 million a year earlier, and lowered the upper end of its 2026 outlook. The result also came in above the €518 million Vara Research consensus.
Why it matters
The company is a major global dialysis provider, and its revised outlook points to pressure from regulatory and inflation headwinds alongside declining US same-market treatments. The change comes weeks after Shervin J. Korangy became CEO.
Revenue rose 1% to €4.94 billion from €4.89 billion a year earlier, while US same-market treatments fell 1.1% in the third quarter, a steeper decline than in the first two quarters of 2026. The revised outlook now ranges from flat to a mid-single-digit percentage decrease.
The players
Fresenius Medical Care
A German dialysis specialist that provides kidney care services and products worldwide.
Shervin J. Korangy
The newly appointed chief executive of Fresenius Medical Care, who took over weeks before the third-quarter results were released.
The details
Fresenius Medical Care, a German dialysis specialist, said regulatory and inflation headwinds weighed on results. Revenue grew 1% while operating income fell, and the company now expects 2026 operating income to range from flat to a mid-single-digit percentage decline.
Timeline
Q1 2026: US same-market treatments declined 0.4%.
Q2 2026: US same-market treatments declined 0.9%.
Q3 2026: Third-quarter results reported, with operating income down 5%.
November 3, 2026: Fresenius Medical Care lowered the upper end of its 2026 outlook.
Market Landscape
Third-quarter operating income beat the €518 million Vara Research consensus, yet the company still trimmed the top of its full-year range. The gap signals that analysts' near-term expectations were more optimistic than the company's view of the full year under current US treatment trends.
Patients receiving dialysis and their care providers may see continued pressure on treatment volumes and pricing as US same-market treatments decline. Investors and employees of the company face a narrower full-year outlook.
The takeaway
Lower treatment volumes in the US and tighter regulatory and inflation conditions are compressing earnings for dialysis providers. Watch whether the company's outlook stabilizes in coming quarters as new leadership sets its strategy.
Further reading
For broader context on the sector, see Healthcare coverage.
Source note: This article includes information reported by Global Banking & Finance Review.
Live Poll
Do you think healthcare is getting better or worse for people like you?
